uniQure (QURE) Chief Medical Officer Abi-Saab Sells $67K of Stock

Walid Abi-Saab, the Chief Medical Officer of uniQure N.V. (NasdaqGS:QURE), sold 1,434 shares of the company on June 26, 2026. The shares were sold at an average price of $46.86, totaling approximately $67,197.24. This transaction was not part of a pre-planned trading strategy.

Insider Buying and Selling at uniQure N.V.

In addition to Abi-Saab's sale, several other insider transactions took place at uniQure. CEO Matthew Kapusta sold 28,716 shares on June 25, 2026, at a price of $50.02 under a pre-planned sale, while also acquiring 28,716 shares at $31.71. On June 24, 2026, he sold 6,696 shares at $50.00 under a planned sale and bought 4,128 shares at $31.71.

Other Institutional Activity in uniQure N.V.

Institutional investors have also been active in uniQure. Avoro Capital Advisors LLC trimmed its position by 190,405 shares, holding about 5.96 million shares worth $97.44 million. Aberdeen Group PLC increased its stake significantly by 1,627,746 shares, bringing its total to 5.31 million shares valued at $86.76 million. Two Sigma Investments, LP boosted its holdings by 1,224,587 shares, now owning 2.68 million shares worth $43.75 million.

uniQure N.V. Stock Up 121.4%

On Wednesday, shares of uniQure N.V. (NasdaqGS:QURE) traded near $46.42. The company has a market capitalization of approximately $3.27 billion. While it currently lacks a meaningful P/E ratio due to not being profitable, it has a beta of 1.001. The stock has seen a 52-week low of $8.73 and a high of $71.50, with a 50-day moving average of $27.22 and a 200-day moving average of $28.28. Its financial health is marked by a current ratio of 10.40 and a quick ratio of 9.97, though it has a high debt-to-equity ratio of 365.37.

Analysts Set New Price Targets

Analysts have recently weighed in on uniQure's prospects. On June 29, 2026, HC Wainwright & Co. maintained a buy rating with a price target of $80. Mizuho also maintained a buy rating on June 25, 2026, setting a target price of $68. Barclays upgraded the stock to a buy rating on June 18, 2026, with a target of $65. The consensus among analysts is strong buy, with a mean target price of $61.68 across 11 opinions.

About uniQure N.V.

uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands, focusing on developing gene therapies for rare and severe diseases. Its flagship product, HEMGENIX, targets hemophilia B, while its pipeline includes treatments for Huntington's disease, epilepsy, ALS, and Fabry disease. Founded in 1998, uniQure has formed partnerships for gene therapy development and supply.

Bottom Line

Walid Abi-Saab's recent share sale at uniQure N.V. is one of several insider transactions, reflecting active trading within the company. Investors keep a close eye on such moves, though it's important to remember these filings reflect past actions. With its ongoing developments in gene therapy, uniQure remains a company to watch in the biotechnology sector.